That article references that.It's about when Traumakine is issued and how severe the patient is.They both have a benefit in covid..the difference being Traumakine will have an ongoing benefit with patients with ARDS not linked to Covid |
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5Think this explains Traumakine and the link to steroids and if proven in current trial then we will have lift off |
Maybe this link works instead:https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa350/5860074 |
 Good reading from Oxford University press for the infectious Diseases Society of America regarding Interferon beta 1a (as is Traumakine, just i.v version of it) in SARS-Cov-2:https://watermark.silverchair.com/jiaa350.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAqowggKmBgkqhkiG9w0BBwagggKXMIICkwIBADCCAowGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMsR56W29h6cavBe6sAgEQgIICXSB5UUIsGKSV3BSOG3Zlu4ayNxGcctqtInfwcUyWXWByV_r9_ck2JBLqdz-pJZ-3KtDFXVUMb6kls_kd2N83HuYGD8LKFY_A9ZDgI-4vGEhD7YXLmlEs8RYSSXO4vOqtpXXVXhcDAZ168kPlu42AgUJX1CGApTrAMhNGi_zDQu_tGyVoD_YOABmNYNzp9E0SmX2zOzTg5uccLDI6aiCatOJw6Dxn4TPH66SoHDCnKtHE4gqI8tJbsmxUUqITQnX03n6IbSrYyi1DPW2SzhO0U39tEpNxLzfDL3gR88AJZekjeTsInHc5aYJlLeqIOxUVLKlOIbtssho0DmA_LcAEi7REeoRWVg0NydADPRGDhD2h1Rk-3bV3dkr5UDfRYg6mfxsDCSRw1Ef1C5p-eCY5FEwOm2ltPxDj1683isJX41TuETaS3dxO8L9mswQWw_IZKDt-7H26ExjX4-1l7hN3lmb9UtueAkQJzKTCxPicJnda9-Ozeb0uXwJgRMOJgHlwYZC0sxmB80CSfaQQEcIlncLVI675E8YkZjfnmpOnCPLM0LBraJ-8DV0xMoA14OOGbSZ_olJtUhz4ArSY2QdKOiraKIGgolDKnuMOZowa0v2En4KfKPwBqXpsU_2tewJkS-hDaSNfSF8K0Sfe-HqDS0fwIlIrrhoi3Oh1ij9DatzFrRtJQktcZjEcYDBz1kiYAC8DvTXRbodJpGom1vYkmD_fbhPW8CfgnWINl3qRUix-8Ha3Zh_CRI4eAnCyvw0gyA7bthkB-seWcc8o5ZoqIiGNFyrJINk0sh298roI |
Slight concern that steroids are now being recommended to treat Covid 19 and yet the Trakumine trial is for patients excluding from using steroids. it will be an interesting outcome. |
Think you'll find they don't just thrown money away at any company. Underpins the funding as we move forward |
You have to wonder what prompted this.
Feedback from Traumakine users?
Opportunitism. Take the loan because it is available now?
A current example of the benefits of having a having a specialised manufacturing capability is OXB. |
Have to believe one day we will open up at £10+ |
Faron's scientific network at work for COVID-19: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5 |
Now that would be interesting for us |
According to Faron's RNS regarding grant from Business Finland as part of Cancer IO on 11.5.2020:- Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium membershttps://cancerio.org/our-partners/From Cancer IO webpage partners include among others: Abbvie, AstraZeneca, Novartis, GSK, Pfizer, Roche.Does this mean Clevegen is to be studied in combination with the drugs of those big pharma companies? |
https://cancerio.org/our-partners/ |
Trust this was the replacement for the company that pulled out last year ? |
I think that news had been discounted already |
Surprisingly muted reaction to the positive news today.....is this just staying under the radar and being missed?
DL |
RNS out - good news on Clevegen; |
Well Markku Jalkanen seems convinced that Traumakine can help treat symptoms of covid19 and for WHO to include it in the solidarity trials suggest it is with merit for fasttrack investigation. Agree about Clevegen . |
I am not convinced about Traumakine, Clevegen is likely to be the game changer here. |
Strange that it's so quiet here considering what they potentially have, i assume it will not be long before FARN is in the spotlight. |
hash - it's completely different FARN is an injectible SNG is nebulised
(I hold both) |
hxxps://www.synairgen.com/covid-19/
Based on my limited understanding of the subject, Synairgen appear to be trying something similar in Southampton university.
Could be competition, but also seems to validate the approach. |
 Faron Pharmaceuticals confident on the potential of both its coronavirus and cancer candidatesIt will also be compared in the study with other treatments, including hydrocortisone medications.These steroid-based interventions, used in patients in respiratory distress, were seen as the potential root cause of a previously failed Faron phase III study of Traumakine.Just weeks after the announcement on REMAP-CAP, Traumakine was also added to the World Health Organisation's Solidarity trial.Faron believes its interferon beta-1a drug may help protect against serious lung complications.It is being administered in combination with the HIV drug lopinavir but, according to Jalkanen, "If it gets to the point where the leak is in the lungs then Traumakine, we believe, is the only drug that can help."The two will be compared with the current standard of care in order to assess efficacy, with early data being available as soon as this month.Faron has donated supplies to treat 2,000 patients, although more people are included in the trial.Licensing partners soughtThe company continues to pursue partnering and licensing discussions for both Traumakine and Clevegen."Clevegen has shown very promising clinical response in MATINS Part I stage, which we believe will transform into significant opportunity when the study moves to the Part II-III expansion stages," Jalkanen said."Traumakine, on the other hand, has a new corticosteroid-free setting through the global REMAP-CAP study, which we believe is one of the most important intensive care studies of the current pandemic environment."Since the beginning of the coronavirus crisis in the UK in mid-March, shares in the biotech have shot up 47% to 367p. |
httpS://www.google.co.uk/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/918664 |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
